Understanding genetic factors in heart damage from chemotherapy
Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs
['FUNDING_CAREER'] · STANFORD UNIVERSITY · NIH-10897272
This study is looking at how your genes might affect the risk of heart damage from chemotherapy, especially from a drug called doxorubicin, and it aims to find ways to protect your heart during cancer treatment by creating heart cells that match your unique genetic makeup.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-10897272 on ClinicalTrials.gov |
What this research studies
This research investigates how genetic variations can influence the risk of heart damage caused by chemotherapy drugs, particularly doxorubicin. By using patient-specific induced pluripotent stem cells (iPSCs), the study aims to create heart cells that mimic the genetic makeup of individual patients. These cells will be used to identify specific genes that, when targeted, could help protect against heart damage during cancer treatment. The ultimate goal is to develop better risk assessment tools and therapies to prevent cardiotoxicity in cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are at risk of developing heart problems due to chemotherapy, particularly those receiving doxorubicin.
Not a fit: Patients who are not undergoing chemotherapy or those without genetic predispositions to cardiotoxicity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatments that minimize heart damage for cancer patients undergoing chemotherapy.
How similar studies have performed: Previous research has shown promise in using iPSCs to study drug responses, indicating that this approach could yield valuable insights into cardiotoxicity.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NISHIGA, MASATAKA — STANFORD UNIVERSITY
- Study coordinator: NISHIGA, MASATAKA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents